Free tool
Rare disease stocks
We cover 4 companies grouped under the Rare disease theme. The median market value in the group is $17.67B. Across the group, the median move over the past trading day is −0.79%. Price change over the past year runs from −80.9% to −31.7% across the middle 80 percent of the group, with a median of −61.0%.
Other lists in this group
SaaSAI applicationsCybersecuritySemiconductor designSemiconductor equipmentFintech softwarePayment processingEcommerce marketplacesStreaming mediaGaming softwareOncologyRare diseaseMedical devicesCell therapyDiagnosticsRegional banksAsset managementGold miningCryptocurrency and digital assetsSpecialty chemicalsAll stocks
Table
4 of 268 companies match these filters.Clear filters
| Ticker | Company | Price | 1M return | YTD return | 1Y return |
|---|---|---|---|---|---|
| VRTX34.SA | Vertex Pharmaceuticals Incorporated | 88.56 BRL | +14.82% | −85.60% | −83.18% |
| 0HD2.L | Alnylam Pharmaceuticals, Inc. | $241.82 | +0.67% | −39.23% | −46.60% |
| SION | Sionna Therapeutics, Inc. | $6.17 | −86.75% | −84.26% | −75.45% |
| MDWD | MediWound Ltd. | $12.70 | −13.13% | −31.05% | −25.29% |
Covers ~22,000 companies across the US, Europe and Asia-Pacific (ex mainland China, Hong Kong and India), refreshed nightly. Every listed stock opens as a full analysis for $9.90.